Brachytherapy in the therapy of prostate cancer - An interesting choice

Wspolczesna Onkologia

Volumn 17, Issue 5, 2013, Pages 407-412

  Skowronek, Janusz ^a,b  

^a GREATER POLAND CANCER CENTER   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

HDR brachytherapy; LDR brachytherapy; Prostate cancer; Seeds

Indexed keywords

COBALT 60; IRIDIUM 192;

BRACHYTHERAPY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEMATURIA; HIGH RISK POPULATION; HUMAN; LOW ENERGY RADIATION; LOW RISK POPULATION; MONOTHERAPY; PATIENT SELECTION; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW; TRANSURETHRAL RESECTION; URINE INCONTINENCE;

EID: 84889782110     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.38557     Document Type: Review

References (61)

1. National Cancer Register Oncology Centre in Warsaw (access: 15.12.2011 - http://85.128.14.124/krn/).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol 2005; 56: 379-96.
4. Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy 2013; 5: 33-41.
5. Wojcieszek P, Białas B. Prostate cancer brachytherapy: guidelines overview. J Contemp Brachytherapy 2012; 4: 116-20.
6. Pieters B, Wijkstra H, van Herk M, Kuipers R, Kaljouw E, de la Rosette J, Koning C. Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning. J Contemp Brachytherapy 2012; 4: 69-74.
7. Kaljouw E, Pieters B, Koedooder K, Lucas C, Koning C. Benefits of a dual sagittal crystal transducer for ultrasound imaging during I-125 seed implantation for permanent prostate brachytherapy. J Contemp Brachytherapy 2012; 4: 141-5.
8. Reed G, Cunha JA, Noworolski S, Kurhanewicz J, Vigneron D, Hsu IC, Pouliot J. Interactive, multi-modality image registrations for combined MRI/MRSI-planned HDR prostate brachytherapy. J Contemp Brachytherapy 2011; 3: 26-31.
9. Hsu I-Ch, Yamada Y, Vigneault E, Pouliot J. American Brachytherapy Society Prostate High-Dose Rate Task Group. Retrieved 15-03-2010, 2010, from http://www.americanbrachytherapy.org/guidelines/index.cfm.
10. Kovács G, Pötter R, Loch T, Hammer J, Kolkman-Deurloo IK, de la Rosette JJ, Bertermann H. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 2005; 74: 137-48.
11. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
12. Erickson BA, Demanes DJ, Ibbott GS, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the performance of High-Dose-Rate Brachytherapy. Int J Radiat Oncology Biol Phys 2011; 79: 641-9.
13. Horwich A, Parker C, Bangma C, Kataja V. ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; Suppl 5: 129-33.
14. Thompson I, Thrasher JB, Aus G, et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-31.
15. Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol 2011; 59: 61-71.
16. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 2011; 29: 362-8.
17. Samuelian JM, Swanson DA, Kudchadker RJ, et al. Long-term tumor control after brachytherapy for base of prostate cancer. J Contemp Brachyther 2011; 3: 183-187.
18. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 3979-3986.
19. Salembier C, Rijnders A, Henry A, Niehoff P, André Siebert F, Hoskin P. Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection. J Contemp Brachytherapy 2013; 5: 63-9.
20. Aronowitz JN, Rivard MJ. The phylogeny of permanent prostate brachytherapy. J Contemp Brachytherapy 2013; 5: 89-92.
21. Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU Int 2005; 96: 43-7.
22. Chicheł A, Kanikowski M, Skowronek J, Dymnicka M, Piotrowski T. Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost. J Contemp Brachytherapy 2009; 1: 11-7.
23. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC. Acute and late complications after radiotherapy for prostate cancer: results of amulticenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005; 61: 1019-34.
24. Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, Jonas U. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006; 24: 289-95.
25. Makarewicz R, Lebioda A, Terlikiewicz J, Biedka M, Wiśniewski T. PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up. J Contemp Brachytherapy 2009; 1: 92-6.
26. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010; 33: 481-8.
27. Jacobs BL, Smith RP, Beriwal S, Benoit RM. Changes in lower urinary tract symptoms after prostate brachytherapy. J Contemp Brachytherapy 2011; 3: 115-20.
28. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I-125 prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011; 81: 376-81.
29. Seppenwoolde Y, Kolkman-Deurloo IK, Sipkema D, de Langen M, Praag J, Jansen P, Heijmen B. HDR prostate monotherapy - dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol 2008; 86: 114-9.
30. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004; 180: 225-32.
31. Kanikowski M, Skowronek J, Chicheł A. HDR brachytherapy of prostate cancer - two year's experience in Greater Poland Cancer Centre. J Contemp Brachytherapy 2009; 1: 137-44.
32. Galalae RM, Kovács G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 81-90.
33. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 316-27.
34. Demanes DJ, Rodriguez RR, Altieri GA. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method. Radiother Oncol 2000; 57: 289-96.
35. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1286-92.
36. Rogers L, Rogers LI. Extended followup of high-dose-rate brachytherapy as monotherapy for intermediate- risk prostate cancer. Brachytherapy 2010; 9 (Suppl. 1): S55-S6.
37. Yoshioka Y, Konishi K, Oh RJ, et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006; 80: 62-8.
38. Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011; 80: 469-75.
39. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001; 49: 61-9.
40. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003; 57: 944-52.
41. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 444-52.
42. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18: 1164-72.
43. Merrick GS, Zelefsky M, Sylvester K, Nag S, Bice W. American Brachytherapy Society Prostate Low-Dose Rate Task Group. http://www. americanbrachytherapy.org/guidelines/prostate-low-doserate-taskgroup.pdf
44. Yoshioka Y, Konishi K, Oh RJ, et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006; 80: 62-8.
45. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as amonotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 2000; 48: 675-81.
46. Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 441-6.
47. Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167: 2443-7.
48. Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997; 37: 565-9.
49. Skowronek J. Modern brachytherapy in the treatment of prostate cancer. Global Journal of Oncologist 2013; 1: 30-41.
50. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-99.
51. Porter AT, Blasko JC, Grimm PD, Reddy SM, Ragde H. Brachytherapy for prostate cancer. Cancer J Clin 1995; 45: 165-78.
52. Garbaulet A, Potter R, Mazeron JJ, Meertens H, Van Limbergen E (eds). The GEC ESTRO Handbook of Brachytherapy. Chapter 20. Brussels 2002; 473-80.
53. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-21.
54. Skowronek J, Kanikowski M, Zwierzchowski G, Chicheł A. Brachyterapia LDR wleczeniu raka gruczołu krokowego. Contemp Oncol (Pozn) 2009; 13: 316-29 [In Polish].
55. Polo A. Image fusion techniques in permanent seed implantation. J Contemp Brachytherapy 2010; 2: 98-106.
56. Pujades MC, Camacho C, Perez-Calatayud J, et al. The use of nomograms in LDR-HDR prostate brachytherapy. J Contemp Brachyther 2011; 3: 121-4.
57. Knaup C, Mavroidis P, Stathakis S, Smith M, Swanson G, Papanikolaou N. Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy. J Contemp Brachytherapy 2011; 3: 125-30.
58. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004; 180: 225-232.
59. Chao ST, Angermeier K, Klein EA, Reddy CA, Ulchaker JC, Stephenson A, Campbell S, Ciezki JP. Prophylactic urethral stenting with Memokath® 028SW in prostate cancer patients undergoing prostate 125I seed implants: phase I/II study. J Contemp Brachytherapy 2011; 3: 18-22.
60. Łuczyńska E, Gasińska A, Wilk W. Microvessels density and expression of vascular endothelial growth factor in clinically localized prostate cancer. Pol J Pathol 2013; 64: 33-8.
61. Łuczyńska E, Gasińska A, Wilk W. Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer. Pol J Pathol 2012; 63: 272-7.